搡老女人多毛老妇女中国,日韩亚洲欧美中文高清在线,人妻少妇一区二区三区,色妞色综合久久夜夜,日本熟妇xxxx

Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant Archaeoglobus fulgidus Probable NH (3)-dependent NAD (+) synthetase CSB-YP518116DOC
CSB-EP518116DOC
CSB-BP518116DOC
CSB-MP518116DOC
CSB-EP518116DOC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Archaeoglobus fulgidus Uncharacterized protein AF_0970 (AF_0970), partial CSB-YP518117DOC1
CSB-EP518117DOC1
CSB-BP518117DOC1
CSB-MP518117DOC1
CSB-EP518117DOC1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Archaeoglobus fulgidus UPF0331 protein AF_0947 (AF_0947) CSB-YP518118DOC
CSB-EP518118DOC
CSB-BP518118DOC
CSB-MP518118DOC
CSB-EP518118DOC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Archaeoglobus fulgidus Ribonuclease Z (rnz) CSB-YP518119DOC
CSB-EP518119DOC
CSB-BP518119DOC
CSB-MP518119DOC
CSB-EP518119DOC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Archaeoglobus fulgidus Uncharacterized protein AF_0924 (AF_0924), partial CSB-YP518120DOC1
CSB-EP518120DOC1
CSB-BP518120DOC1
CSB-MP518120DOC1
CSB-EP518120DOC1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Archaeoglobus fulgidus Uncharacterized protein AF_0912 (AF_0912), partial CSB-YP518121DOC
CSB-EP518121DOC
CSB-BP518121DOC
CSB-MP518121DOC
CSB-EP518121DOC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Archaeoglobus fulgidus tRNA-splicing endonuclease (endA) CSB-YP518122DOC
CSB-EP518122DOC
CSB-BP518122DOC
CSB-MP518122DOC
CSB-EP518122DOC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Archaeoglobus fulgidus Glutamyl-tRNA (Gln) amidotransferase subunit D CSB-YP518123DOC
CSB-EP518123DOC
CSB-BP518123DOC
CSB-MP518123DOC
CSB-EP518123DOC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Archaeoglobus fulgidus Glycerol-3-phosphate dehydrogenase [NAD (P)+] CSB-YP518124DOC
CSB-EP518124DOC
CSB-BP518124DOC
CSB-MP518124DOC
CSB-EP518124DOC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Archaeoglobus fulgidus tRNA-splicing ligase RtcB (rtcB) CSB-YP518125DOC
CSB-EP518125DOC
CSB-BP518125DOC
CSB-MP518125DOC
CSB-EP518125DOC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Archaeoglobus fulgidus Uncharacterized protein AF_0842 (AF_0842), partial CSB-YP518126DOC1
CSB-EP518126DOC1
CSB-BP518126DOC1
CSB-MP518126DOC1
CSB-EP518126DOC1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Archaeoglobus fulgidus Desulfoferrodoxin homolog (AF_0833) CSB-YP518127DOC
CSB-EP518127DOC
CSB-BP518127DOC
CSB-MP518127DOC
CSB-EP518127DOC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Archaeoglobus fulgidus tRNA (guanine (26)-N (2))-dimethyltransferase CSB-YP518128DOC
CSB-EP518128DOC
CSB-BP518128DOC
CSB-MP518128DOC
CSB-EP518128DOC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Archaeoglobus fulgidus Uncharacterized protein AF_0803 (AF_0803) CSB-YP518129DOC
CSB-EP518129DOC
CSB-BP518129DOC
CSB-MP518129DOC
CSB-EP518129DOC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Archaeoglobus fulgidus Uncharacterized protein AF_0789 (AF_0789) CSB-YP518130DOC
CSB-EP518130DOC
CSB-BP518130DOC
CSB-MP518130DOC
CSB-EP518130DOC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Archaeoglobus fulgidus Uncharacterized protein AF_0771 (AF_0771), partial CSB-YP518131DOC
CSB-EP518131DOC
CSB-BP518131DOC
CSB-MP518131DOC
CSB-EP518131DOC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Archaeoglobus fulgidus Large ribosomal subunit protein eL8 (rpl7ae) CSB-YP518132DOC
CSB-EP518132DOC
CSB-BP518132DOC
CSB-MP518132DOC
CSB-EP518132DOC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Archaeoglobus fulgidus Uncharacterized protein AF_0758 (AF_0758) CSB-YP518133DOC
CSB-EP518133DOC
CSB-BP518133DOC
CSB-MP518133DOC
CSB-EP518133DOC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Archaeoglobus fulgidus Uncharacterized protein AF_0748 (AF_0748) CSB-YP518134DOC
CSB-EP518134DOC
CSB-BP518134DOC
CSB-MP518134DOC
CSB-EP518134DOC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Archaeoglobus fulgidus Putative uncharacterized protein AF_0740 (AF_0740) CSB-YP518135DOC
CSB-EP518135DOC
CSB-BP518135DOC
CSB-MP518135DOC
CSB-EP518135DOC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長度(全長或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://www.pptc.cn/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>